Personalised melanoma vaccine reduces recurrence risk by 42%, trial finds

An Australian-led phase III trial shows the custom-made mRNA vaccine intismeran combined with immunotherapy significantly improves outcomes for high-risk melanoma patients.

A personalised mRNA vaccine has reduced the risk of melanoma recurrence or death by 42% when used alongside immunotherapy, according to results from an Australian-led phase III clinical trial. The trial included 1,137 patients whose melanoma had been surgically removed but who remained at high risk of the cancer returning. All participants received the immunotherapy drug pembrolizumab for twelve months, while some also received the custom-made vaccine, intismeran.

At two years post-treatment, 82% of those receiving the combination of intismeran and pembrolizumab were alive and recurrence-free, compared with 70% of participants treated with pembrolizumab alone. The vaccine is custom-made to target genetic mutations unique to an individual's melanoma, targeting up to 34 mutations.

Prof Georgina Long, medical director of the Melanoma Institute Australia, said the research will allow scientists to harness immune systems in more personalised ways. Long will present the results at the European Society for Medical Oncology’s annual congress in Madrid on the weekend. The findings have been accepted for publication in the New England Journal of Medicine and will undergo peer review.

Dr Jessamy Tiffen, acting deputy director of the Centre for Cancer Innovations at the Centenary Institute, said the deeply personalised nature of the treatment is something researchers have been striving to achieve for decades. She noted that a significant portion of patients do not respond to the vaccine in the first instance and that cancer cells can adapt to evade treatment.

Prof Christopher Sweeney, director of the South Australian immunoGENomics Cancer Institute at Adelaide University, described the vaccine as a step-change approach to improve the body's immune system. He said more research is needed to see if the approach is effective in patients who have cancer we can see or those not responsive to pembrolizumab.

The personalised vaccine will not be available as a standard melanoma treatment until it has gone through further study and regulatory review, a process that may take several years. Drug manufacturers said it is too early to tell from the data whether the combination treatment improved long-term survival.

Key facts

  • The combination of intismeran and pembrolizumab reduced the risk of melanoma recurrence or death by 42% compared to pembrolizumab alone.
  • The phase III trial involved 1,137 patients across 157 sites worldwide.
  • Intismeran is a bespoke mRNA vaccine that targets up to 34 gene mutations unique to each patient.

Three perspectives

Neutral

The personalised vaccine will not be available as a standard treatment until it completes further study and regulatory review, which may take several years.

Positive

The trial results represent a foundational shift in cancer approach, allowing scientists to harness the immune system in more personalised ways.

Negative

A significant portion of patients do not respond to the vaccine in the first instance.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Adelaide childcare worker diagnosed with tuberculosis, about 100 children exposed
Next storyAdelaide childcare worker diagnosed with tuberculosis, about 100 children exposed

All sections

Edition